TWI726540B - 包含第一親水性嵌段、第二疏水性嵌段及能夠特異性結合至硫醇之官能基的嵌段共聚物 - Google Patents
包含第一親水性嵌段、第二疏水性嵌段及能夠特異性結合至硫醇之官能基的嵌段共聚物 Download PDFInfo
- Publication number
- TWI726540B TWI726540B TW108146271A TW108146271A TWI726540B TW I726540 B TWI726540 B TW I726540B TW 108146271 A TW108146271 A TW 108146271A TW 108146271 A TW108146271 A TW 108146271A TW I726540 B TWI726540 B TW I726540B
- Authority
- TW
- Taiwan
- Prior art keywords
- cancer
- block copolymer
- block
- functional group
- weight
- Prior art date
Links
- 229920001400 block copolymer Polymers 0.000 title claims abstract description 107
- 125000000524 functional group Chemical group 0.000 title claims abstract description 81
- 230000027455 binding Effects 0.000 title claims abstract description 35
- 125000003396 thiol group Chemical class [H]S* 0.000 title claims abstract description 22
- 230000002209 hydrophobic effect Effects 0.000 title abstract description 49
- 238000012377 drug delivery Methods 0.000 claims description 65
- -1 neuroleptics Substances 0.000 claims description 59
- 229940079593 drug Drugs 0.000 claims description 55
- 239000003814 drug Substances 0.000 claims description 55
- 210000004027 cell Anatomy 0.000 claims description 54
- 210000002865 immune cell Anatomy 0.000 claims description 44
- 206010028980 Neoplasm Diseases 0.000 claims description 40
- 201000011510 cancer Diseases 0.000 claims description 37
- 210000000822 natural killer cell Anatomy 0.000 claims description 30
- 230000001093 anti-cancer Effects 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 125000002947 alkylene group Chemical group 0.000 claims description 23
- 239000002105 nanoparticle Substances 0.000 claims description 21
- 239000002246 antineoplastic agent Substances 0.000 claims description 18
- 125000005647 linker group Chemical group 0.000 claims description 14
- 125000003342 alkenyl group Chemical group 0.000 claims description 13
- 229940041181 antineoplastic drug Drugs 0.000 claims description 13
- 125000000304 alkynyl group Chemical group 0.000 claims description 12
- 125000002723 alicyclic group Chemical group 0.000 claims description 11
- 239000003242 anti bacterial agent Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 5
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims description 5
- 229940035676 analgesics Drugs 0.000 claims description 4
- 239000000730 antalgic agent Substances 0.000 claims description 4
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 239000003246 corticosteroid Substances 0.000 claims description 4
- 210000004443 dendritic cell Anatomy 0.000 claims description 4
- 125000002228 disulfide group Chemical group 0.000 claims description 4
- 235000004626 essential fatty acids Nutrition 0.000 claims description 4
- 210000002540 macrophage Anatomy 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 229940121375 antifungal agent Drugs 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 229960001334 corticosteroids Drugs 0.000 claims description 3
- 229940035363 muscle relaxants Drugs 0.000 claims description 3
- 239000003158 myorelaxant agent Substances 0.000 claims description 3
- 206010000830 Acute leukaemia Diseases 0.000 claims description 2
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 201000001342 Fallopian tube cancer Diseases 0.000 claims description 2
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims description 2
- 229940122236 Histamine receptor antagonist Drugs 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 206010061252 Intraocular melanoma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims description 2
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 2
- 206010034299 Penile cancer Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims description 2
- 206010046392 Ureteric cancer Diseases 0.000 claims description 2
- 206010046431 Urethral cancer Diseases 0.000 claims description 2
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 206010046543 Urinary incontinence Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 201000005969 Uveal melanoma Diseases 0.000 claims description 2
- 206010047741 Vulval cancer Diseases 0.000 claims description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 2
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 2
- 230000001430 anti-depressive effect Effects 0.000 claims description 2
- 230000003178 anti-diabetic effect Effects 0.000 claims description 2
- 230000003556 anti-epileptic effect Effects 0.000 claims description 2
- 230000000843 anti-fungal effect Effects 0.000 claims description 2
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 2
- 230000000078 anti-malarial effect Effects 0.000 claims description 2
- 230000002460 anti-migrenic effect Effects 0.000 claims description 2
- 230000001022 anti-muscarinic effect Effects 0.000 claims description 2
- 239000000883 anti-obesity agent Substances 0.000 claims description 2
- 230000000648 anti-parkinson Effects 0.000 claims description 2
- 230000001028 anti-proliverative effect Effects 0.000 claims description 2
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 2
- 239000001961 anticonvulsive agent Substances 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- 229960002708 antigout preparations Drugs 0.000 claims description 2
- 239000003430 antimalarial agent Substances 0.000 claims description 2
- 239000003096 antiparasitic agent Substances 0.000 claims description 2
- 229940125687 antiparasitic agent Drugs 0.000 claims description 2
- 239000000939 antiparkinson agent Substances 0.000 claims description 2
- 239000003904 antiprotozoal agent Substances 0.000 claims description 2
- 239000003200 antithyroid agent Substances 0.000 claims description 2
- 229940043671 antithyroid preparations Drugs 0.000 claims description 2
- 239000002249 anxiolytic agent Substances 0.000 claims description 2
- 230000000949 anxiolytic effect Effects 0.000 claims description 2
- 229940005530 anxiolytics Drugs 0.000 claims description 2
- 239000002876 beta blocker Substances 0.000 claims description 2
- 229940097320 beta blocking agent Drugs 0.000 claims description 2
- 239000000496 cardiotonic agent Substances 0.000 claims description 2
- 230000003177 cardiotonic effect Effects 0.000 claims description 2
- 229940044683 chemotherapy drug Drugs 0.000 claims description 2
- 208000024207 chronic leukemia Diseases 0.000 claims description 2
- 239000002475 cognitive enhancer Substances 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 229940111134 coxibs Drugs 0.000 claims description 2
- 208000030381 cutaneous melanoma Diseases 0.000 claims description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 229940030606 diuretics Drugs 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 239000004083 gastrointestinal agent Substances 0.000 claims description 2
- 229940127227 gastrointestinal drug Drugs 0.000 claims description 2
- 239000003163 gonadal steroid hormone Substances 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 239000003326 hypnotic agent Substances 0.000 claims description 2
- 230000000147 hypnotic effect Effects 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 2
- 229940041033 macrolides Drugs 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 210000000274 microglia Anatomy 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 claims description 2
- 201000002575 ocular melanoma Diseases 0.000 claims description 2
- 239000002357 osmotic agent Substances 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000003708 skin melanoma Diseases 0.000 claims description 2
- 201000002314 small intestine cancer Diseases 0.000 claims description 2
- 239000000021 stimulant Substances 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 239000003204 tranquilizing agent Substances 0.000 claims description 2
- 230000002936 tranquilizing effect Effects 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 206010046885 vaginal cancer Diseases 0.000 claims description 2
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 2
- 201000005102 vulva cancer Diseases 0.000 claims description 2
- 206010012335 Dependence Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 230000000842 anti-protozoal effect Effects 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 201000000360 urethra cancer Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 239000003981 vehicle Substances 0.000 description 61
- 229920001477 hydrophilic polymer Polymers 0.000 description 35
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 33
- 229920001600 hydrophobic polymer Polymers 0.000 description 31
- 150000001875 compounds Chemical class 0.000 description 30
- 230000001939 inductive effect Effects 0.000 description 28
- 238000000034 method Methods 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 21
- 239000000693 micelle Substances 0.000 description 20
- 150000003573 thiols Chemical class 0.000 description 19
- 229960004679 doxorubicin Drugs 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- 230000002378 acidificating effect Effects 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 16
- 229920000642 polymer Polymers 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 125000002091 cationic group Chemical group 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 239000002904 solvent Substances 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- JKKSCGHDRHRWOQ-UHFFFAOYSA-N ciliobrevin D Chemical compound ClC1=CC(Cl)=CC=C1C(=O)C(C#N)=C1NC2=CC(Cl)=CC=C2C(=O)N1 JKKSCGHDRHRWOQ-UHFFFAOYSA-N 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 229920001577 copolymer Polymers 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 125000004450 alkenylene group Chemical group 0.000 description 6
- 125000004419 alkynylene group Chemical group 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
- 229920000570 polyether Polymers 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 108010025020 Nerve Growth Factor Proteins 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate group Chemical group C(C=C)(=O)[O-] NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 239000007795 chemical reaction product Substances 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 238000006116 polymerization reaction Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102000007072 Nerve Growth Factors Human genes 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 239000003443 antiviral agent Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229940088623 biologically active substance Drugs 0.000 description 4
- 229960000182 blood factors Drugs 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 229920002635 polyurethane Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 102000003390 tumor necrosis factor Human genes 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 description 3
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 239000003900 neurotrophic factor Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- 102100026277 Alpha-galactosidase A Human genes 0.000 description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 229940127093 camptothecin Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229940047120 colony stimulating factors Drugs 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 229920000359 diblock copolymer Polymers 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 108010039650 imiglucerase Proteins 0.000 description 2
- 229960002127 imiglucerase Drugs 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229960000965 nimesulide Drugs 0.000 description 2
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229920000962 poly(amidoamine) Polymers 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000002601 radiography Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000003488 releasing hormone Substances 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 229960002004 valdecoxib Drugs 0.000 description 2
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- DDYAPMZTJAYBOF-ZMYDTDHYSA-N (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(1S)-1-carboxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid Chemical class [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DDYAPMZTJAYBOF-ZMYDTDHYSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- OBYJFWVFCFYKNY-UHFFFAOYSA-N 1-prop-2-ynylpyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1CC#C OBYJFWVFCFYKNY-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- JVJUWEFOGFCHKR-UHFFFAOYSA-N 2-(diethylamino)ethyl 1-(3,4-dimethylphenyl)cyclopentane-1-carboxylate;hydrochloride Chemical compound Cl.C=1C=C(C)C(C)=CC=1C1(C(=O)OCCN(CC)CC)CCCC1 JVJUWEFOGFCHKR-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- OXEZLYIDQPBCBB-UHFFFAOYSA-N 4-(3-piperidin-4-ylpropyl)piperidine Chemical compound C1CNCCC1CCCC1CCNCC1 OXEZLYIDQPBCBB-UHFFFAOYSA-N 0.000 description 1
- YYLDMKOEUDZXAW-UHFFFAOYSA-N 5,5-diphenylpyrazole-3,4-dione Chemical compound C1(=CC=CC=C1)C1(C(C(N=N1)=O)=O)C1=CC=CC=C1 YYLDMKOEUDZXAW-UHFFFAOYSA-N 0.000 description 1
- FIHBHSQYSYVZQE-UHFFFAOYSA-N 6-prop-2-enoyloxyhexyl prop-2-enoate Chemical compound C=CC(=O)OCCCCCCOC(=O)C=C FIHBHSQYSYVZQE-UHFFFAOYSA-N 0.000 description 1
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- OSDWBNJEKMUWAV-UHFFFAOYSA-N Allyl chloride Chemical compound ClCC=C OSDWBNJEKMUWAV-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 102100033367 Appetite-regulating hormone Human genes 0.000 description 1
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 description 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
- 102000007536 B-Cell Activation Factor Receptor Human genes 0.000 description 1
- 108010046304 B-Cell Activation Factor Receptor Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 0 C[C@](**(*1CC1)N)N Chemical compound C[C@](**(*1CC1)N)N 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000012286 Chitinases Human genes 0.000 description 1
- 108010022172 Chitinases Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 102100028944 Dual specificity protein phosphatase 13 isoform B Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100021977 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Human genes 0.000 description 1
- 108050004000 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Proteins 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 102000004862 Gastrin releasing peptide Human genes 0.000 description 1
- 108090001053 Gastrin releasing peptide Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 108010017544 Glucosylceramidase Proteins 0.000 description 1
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 1
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 101000718525 Homo sapiens Alpha-galactosidase A Proteins 0.000 description 1
- 101000838551 Homo sapiens Dual specificity protein phosphatase 13 isoform A Proteins 0.000 description 1
- 101000838549 Homo sapiens Dual specificity protein phosphatase 13 isoform B Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000004627 Iduronidase Human genes 0.000 description 1
- 108010003381 Iduronidase Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 108010054267 Interferon Receptors Proteins 0.000 description 1
- 102000001617 Interferon Receptors Human genes 0.000 description 1
- 102000007438 Interferon alpha-beta Receptor Human genes 0.000 description 1
- 108010086140 Interferon alpha-beta Receptor Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 101710105045 Lipoprotein E Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 238000006957 Michael reaction Methods 0.000 description 1
- 102400000569 Myeloperoxidase Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- 108010056852 Myostatin Proteins 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 102000010803 Netrins Human genes 0.000 description 1
- 108010063605 Netrins Proteins 0.000 description 1
- 102100021584 Neurturin Human genes 0.000 description 1
- 108010015406 Neurturin Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102100031538 Phosphatidylcholine-sterol acyltransferase Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 102000003743 Relaxin Human genes 0.000 description 1
- 108090000103 Relaxin Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 102100022831 Somatoliberin Human genes 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
- 108010016283 TCF Transcription Factors Proteins 0.000 description 1
- 102000000479 TCF Transcription Factors Human genes 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108010079274 Thrombomodulin Proteins 0.000 description 1
- 102100026966 Thrombomodulin Human genes 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 108010030291 alpha-Galactosidase Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 238000011224 anti-cancer immunotherapy Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 230000028600 axonogenesis Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000034127 bone morphogenesis Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
- 229950008486 carperitide Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- DDPFHDCZUJFNAT-PZPWKVFESA-N chembl2104402 Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CCCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 DDPFHDCZUJFNAT-PZPWKVFESA-N 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000002442 collagenase inhibitor Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 108700032313 elcatonin Proteins 0.000 description 1
- 229960000756 elcatonin Drugs 0.000 description 1
- 239000005712 elicitor Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108010077689 gamma-aminobutyryl-2-methyltryptophyl-2-methyltryptophyl-2-methyltryptophyl-lysinamide Proteins 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006510 metastatic growth Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- ZDHCZVWCTKTBRY-UHFFFAOYSA-N omega-Hydroxydodecanoic acid Natural products OCCCCCCCCCCCC(O)=O ZDHCZVWCTKTBRY-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000333 poly(propyleneimine) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000101 thioether group Chemical group 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/321—Polymers modified by chemical after-treatment with inorganic compounds
- C08G65/325—Polymers modified by chemical after-treatment with inorganic compounds containing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
- C08G81/02—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers at least one of the polymers being obtained by reactions involving only carbon-to-carbon unsaturated bonds
- C08G81/024—Block or graft polymers containing sequences of polymers of C08C or C08F and of polymers of C08G
- C08G81/025—Block or graft polymers containing sequences of polymers of C08C or C08F and of polymers of C08G containing polyether sequences
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/55—Lung
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G2/00—Addition polymers of aldehydes or cyclic oligomers thereof or of ketones; Addition copolymers thereof with less than 50 molar percent of other substances
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
本發明有關於一種嵌段共聚物,其包含一親水性第一嵌段、一疏水性第二嵌段及一能夠特異性結合至硫醇之官能基。
Description
發明領域
本揭示係有關於一種嵌段共聚物,其包含一親水性第一嵌段、一疏水性第二嵌段及一能夠特異性結合至硫醇之官能基。
發明背景
抗癌化學療法及放射療法是廣為人知用於治療癌症(現代人之代表性難治疾病)之療法,其等在病人體內會引起非特異性藥理作用,因此存在療效差及在病患體內引起各種副作用之問題。
為了解決此等問題,近來已經出現基於人體內之免疫反應的新治療法。其中,T細胞及自然殺手細胞具有準確辨識及攻擊癌細胞之特異性機制,因此具有在不傷害正常細胞之情況下治療癌症之可能性,此不同於習知的抗癌化學/放射療法。
然而,由於癌細胞透過其等之基因變異逃避免疫、個體免疫細胞缺少毒性以及諸如此類,所以單獨免疫細胞很難達到完全的治療癌症。
因此, 為了解決這些問題,需要一種容許抗癌化學藥物與免疫細胞同時作用在癌上以增加療效之方法,還需要建立一種用以防止抗癌化學藥物作用在正常組織上之智能藥物遞輸系統。
技術問題
為解決上述問題,本發明人已製得一種嵌段共聚物,其包含一親水性第一嵌段;一疏水性第二嵌段,其包括一會在pH 4.5至7之條件下被分解或變成陽離子型的單元;及一能夠特異性結合至硫醇之官能基,及已鑑定出該嵌段共聚物可附著於存在免疫細胞表面上之硫醇,且可攜帶藥物並在酸性條件下釋出該藥物,以致增強該免疫細胞之作用,從而完成本發明。
據此,本發明之一目的是提供一種嵌段共聚物,其容許其攜帶的藥物與免疫細胞同時作用,因此能夠預防或治療癌症疾病或病症或各種感染。解決問題之方法
為實現以上目的,根據本發明之一實施例,提供一種嵌段共聚物,其包含一親水性第一嵌段;一疏水性第二嵌段;及一能夠特異性結合至硫醇之官能基,其中該疏水性第二嵌段在其主鏈中包括一在pH 4.5至7之條件下被分解的單元、在其主鏈或側鏈中包括一在4.5至7之條件下變成陽離子型的單元,或包括該二種單元。
根據本發明之另一實施例,提供一種奈米粒子,其包含該嵌段共聚物。
根據本發明之又另一實施例,提供一種藥物遞輸載具,其包含該奈米粒子及一藥物。
根據本發明之又再另一實施例,提供一種修飾細胞,其包含該藥物遞輸載具及一免疫細胞。
根據本發明之又再另一實施例,提供一種用於抗癌用途的藥學組成物,其包含該嵌段共聚物及一抗癌藥物。
此外,根據本發明之又再另一實施例,提供一種用於抗癌用途或用於預防或治療感染的藥學組成物,其包含該嵌段共聚物及一免疫細胞。本發明之有利作用
根據本發明之嵌段共聚物能特異性結合至存在免疫細胞表面上之硫醇,且僅能在由該免疫細胞引起的酸性條件下進行結構改變,以便釋出藥物。因此,該嵌段共聚物可透過化學療法增強免疫細胞的抗癌能力或預防或治療感染之能力,同時抑制其攜帶的藥物之非特異性副作用。
實施本發明之最佳模式
在本發明之一態樣中,提供一種在pH下經歷結構改變的嵌段共聚物。
在本發明之一實施例中,提供一種嵌段共聚物,其包含一親水性第一嵌段;一疏水性第二嵌段;及一能夠特異性結合至硫醇之官能基,其中該疏水性第二嵌段在其主鏈中包括一在4.5至7條件下被分解的單元、在其主鏈或側鏈中包括一在pH 4.5至7條件下變成陽離子型的單元,或包括該二種單元。
在本發明之一實施例中,該親水性第一嵌段意指在水中具高溶解度的聚合物。例如,在室溫下,該親水性第一嵌段作為聚合物溶解於水中之情況下,可能不會表現出混濁。此外,該親水性第一嵌段可包括聚(乙烯醇)、聚(乙烯吡咯啶酮)、聚(丙烯醯胺)、聚(㗁唑啉)或聚(醚)或此等之一共聚物。具體地,該親水性第一嵌段是聚(醚)且可包括聚(乙二醇)、聚葡萄糖、聚甘露糖、聚三葡萄糖或纖維素或此等之一共聚物。更具體地,該親水性第一嵌段可包括聚(乙二醇)。
在該式中,D1
是C1
或C2
伸烷基基團,及D2
及D3
各自獨立地選自氫;鹵素;羥基基團;及甲基基團。
同時,在本發明之一實施例中,該疏水性第二嵌段意指在水中具低溶解度的聚合物。例如,在室溫下,該疏水性第二嵌段溶解於水中之情況下,可能會表現出混濁。此外,該疏水性第二嵌段可在其主鏈中包括一會在pH 4.5至7之條件下被分解的單元,在其主鏈或側鏈中包括一會在pH 4.5至7之條件下變成陽離子型的單元,或包括二種單元。
具體地,該疏水性第二嵌段可在其主鏈中包括一會在pH 5.8至6.8之條件下被分解的單元,在其主鏈或側鏈中包括一會在pH 5.8至6.8之條件下變成陽離子型的單元,或包括二種單元。在此,該會在例如pH 4.5至7.0或pH 5.8至6.8之酸性條件下變成陽離子型的單元,可為其共軛酸具有pKa為4.5至7.0或5.8至6.8的單元。還有在此,該會在酸性條件下被分解或變成陽離子型的單元,可為一不會在非酸性條件下(諸如超過pH 7.0或超過pH 6.8之條件下)被分解或變成陽離子型的單元。
由於包含此一會在酸性條件下被分解或變成陽離子型的單元,因此當親水性/疏水性之平衡因疏水性基團於酸性條件下(諸如pH 4.5至7.0或pH 5.8至6.8之條件)變成陽離子型而瓦解時,或當該疏水性基團被分解時,本發明之嵌段共聚物可經歷結構改變。因此,在攜帶藥物之情況下,本發明之該實施例之嵌段共聚物可具有選擇性地在酸性條件下釋出該藥物的特徵。特別是,在投與至一受試者之情況下,該嵌段共聚物可結合至已經存在該受試者中之免疫細胞,或結合至額外加至該受試者之免疫細胞,因此可選擇性地在該免疫細胞發揮其作用時所形成的酸性環境下釋出藥物。如此,本發明之嵌段共聚物可增強該免疫細胞的能力,同時抑制其攜帶的藥物之非特異性副作用。
具體地,在該疏水性第二嵌段中,包括會在諸如pH 4.5至7.0或pH 5.8至6.8之酸性條件下被分解的單元之聚合物,可包括聚(乳酸)、聚(乙交酯)、聚(縮醛)、聚(縮酮)或聚(胺酯)或此等之一共聚物。此外,包括會在諸如pH 4.5至7.0或pH 5.8至6.8之酸性條件下變成陽離子型的單元之聚合物,可包括聚(乙烯亞胺)、聚(丙烯亞胺)、聚(胺酯)、聚(醯胺基胺)、聚(甲基丙烯酸二甲胺乙酯)、聚(離胺酸)、幾丁聚醣或明膠或此等之一共聚物。更具體地,該疏水性第二嵌段可包括聚(胺酯),作為包括會在酸性條件下被分解的單元及會在酸性條件下變成陽離子型的單元二者之聚合物。更具體地,該疏水性第二嵌段可包括以式2表示的單元,基本上由以式2表示的單元構成或由以式2表示的單元構成。
[式2]
在該式中,A1
及A3
各自獨立地選自C1
至C5
直鏈或支鏈伸烷基基團;C2
至C5
直鏈或支鏈伸烯基(alkenylene)基團;及C2
至C5
直鏈或支鏈伸炔基(alkynylene)基團,A2
係選自C1
至C10
直鏈或支鏈伸烷基基團;C2
至C10
直鏈或支鏈伸烯基基團;及C2
至C10
直鏈或支鏈伸炔基基團,及B1
及B3
各自獨立地選自C1
至C10
直鏈或支鏈伸烷基基團;C2
至C10
直鏈或支鏈伸烯基基團;及C2
至C10
直鏈或支鏈伸炔基基團,及B2
及B4
各自獨立地選自氫;鹵素;C1
至C10
直鏈或支鏈烷基基團;C2
至C10
直鏈或支鏈烯基基團;C2
至C10
直鏈或支鏈炔基基團;C1
至C10
直鏈或支鏈伸烷基基團;C2
至C10
直鏈或支鏈伸烯基基團;及C2
至C10
直鏈或支鏈伸炔基基團,其中B1
與B2
可彼此連接形成一C3
至C20
脂環族或芳族環;及B3
與B4
可彼此連接形成一C3
至C20
脂環族或芳族環。
更具體地,在該式中,A1
及A3
可各自獨立地為C1
至C5
直鏈或支鏈伸烷基基團。A2
可為C1
至C10
直鏈或支鏈伸烷基基團。B1
及B3
可各自獨立地為C1
至C10
直鏈或支鏈伸烷基基團。B2
及B4
可各自獨立地選自氫;C1
至C10
直鏈或支鏈烷基基團;及C1
至C10
直鏈或支鏈伸烷基基團。B1
與B2
可彼此連接形成C4
至C10
脂環族環。B3
與B4
可彼此連接形成C4
至C10
脂環族環。
更具體地,在該式中,A1
及A3
各自獨立地為C1
至C5
直鏈或支鏈伸烷基基團,A2
是C1
至C10
直鏈或支鏈伸烷基基團,B1
及B3
各自獨立地為C1
至C10
直鏈或支鏈伸烷基基團,及B2
及B4
各自獨立地選自氫;C1
至C10
直鏈或支鏈烷基基團;及C1
至C10
直鏈或支鏈伸烷基基團,其中B1
與B2
可彼此連接形成C4
至C10
脂環族環,及B3
與B4
可彼此連接形成C4
至C10
脂環族環。
在本發明之一實施例中,該能夠特異性結合至硫醇之官能基可為例如二硫化物基團、順丁烯二亞醯胺基團、烯基基團或炔基基團或其組合。選擇性地,該官能基可為該二硫化物基團之衍生物、該順丁烯二亞醯胺基團之衍生物、該烯基基團之衍生物或該炔基基團之衍生物或其組合。在此,該二硫化物之衍生物可意指通過一保護基團與該二硫化物基團之結合所形成的官能基。在此,除非另有說明,否則該烯基基團或炔基基團可分別意指,但不限於,具有2至60個碳原子、具有雙鍵或三鍵及包括直鏈或支鏈基團之官能基。該能夠特異性結合至硫醇之官能基可具體地為順丁烯二亞醯胺基團或其衍生物。
更具體地,本發明之實施例之嵌段共聚物可包括聚(醚)作為該親水性第一嵌段、包括聚(胺酯)作為該疏水性第二嵌段及包括一能夠特異性結合至硫醇之官能基。
更具體地,本發明之實施例之嵌段共聚物可包括一親水性第一嵌段,其包括以式1表示的單元;包括一疏水性第二嵌段,其包括以式2表示的單元;及包括一能夠特異性結合至硫醇之官能基。
在該式中,A1
至A3
及B1
至B4
如式2所述,D1
至D3
如式1所述。L1
是一連接子,p及q各自獨立地為1至100之整數。具體地,p及q可各自獨立地為5至100之整數。更具體地,p可為10至80之整數或20至70之整數,及q可為1至30之整數或5至25之整數。然而,p及q不特別限於此。此外,p/q可為(1:5)至(5:1)。具體地,p/q可為(1:1)至(5:1)。
另一方面,該連接子L1
可將該親水性第一嵌段與該疏水性第二嵌段彼此連接,但沒有特別限制,只要該連接子L1
不會抑制本發明之嵌段共聚物之作用即可。只要該連接子L1
不會抑制本發明之嵌段共聚物之作用,則該連接子L1
之分子量沒有特別限制,且可為例如10至2,000Da、10至1,800Da、10至1,600Da或20至1,000Da。該連接子L1
可具有從常用於將二個或多個聚合物彼此連接之化合物/官能基衍生而來之結構。例如,L1
可以式4表示。
[式4]
在該式中,B3
及B4
如式2所述,及E1
是一從能夠與胺反應之官能基衍生而來的單元。
該能夠與胺反應之官能基之例子,可包括烯基基團、炔基基團或丙烯酸酯基團,及該從能夠與胺反應之官能基衍生而來的單元之例子,可包括*-C2
H4
-*、*-C2
H2
-*及*-OOC-C2
H4
-*。然而,L1
之結構不特別限於此。
在該式中,A1
至A3
及B1
至B4
如式2所述,D1
至D3
如式1所述,及L1
如式4所述。此外,D1
及D4
可各自獨立地為C1
或C2
伸烷基基團,D2
、D3
、D5
及D6
可各自獨立地選自氫;鹵素;羥基基團;及甲基基團,L2
可為一連接子,及p、q及r可各自獨立地為從1至100之整數或從5至100之整數。具體地,(p + r)/q可為(1:10)至(10:1)、(1:5)至(10:1)、(1:3)至(10:1)或(1:1)至(10:1)。
另一方面,與L1
相同,該連接子L2
可將該親水性第一嵌段與該疏水性第二嵌段彼此連接,且沒有特別限制,除非該連接子L2
會抑制本發明之嵌段共聚物之作用。該連接子L2
之分子量亦如針對L1
之說明,及該連接子L2
可具有從常用於將二或多個聚合物彼此連接之化合物/官能基衍生而來之結構。例如,L2
可以式6表示。
[式6]
在該式中,B1
係選自C1
至C10
直鏈或支鏈伸烷基基團;C2
至C10
直鏈或支鏈伸烯基基團;及C2
至C10
直鏈或支鏈伸炔基基團,B2
係選自氫;鹵素;C1
至C10
直鏈或支鏈烷基基團;C2
至C10
直鏈或支鏈烯基基團;C2
至C10
直鏈或支鏈炔基基團;C1
至C10
直鏈或支鏈伸烷基基團;C2
至C10
直鏈或支鏈伸烯基基團;及C2
至C10
直鏈或支鏈伸炔基基團,及E2
是一從能夠與胺反應之官能基衍生而來的單元,其中B1
與B2
可彼此連接形成一C3
至C20
脂環族或芳族環。B1
及B2
如式2所述。
該能夠與胺反應之官能基之例子,可包括烯基基團、炔基基團或丙烯酸酯基團,及該從能夠與胺反應之官能基衍生而來的單元之例子,可包括*-C2
H4
-*、*-C2
H2
-*及*-OOC-C2
H4
-*。然而,L2
之結構不特別限於此。
在該式中,p及r可各自獨立地為1至100之整數、5至100之整數、5至90之整數、10至80之整數、20至65之整數或30至60之整數,及q可為1至60之整數、1至45之整數、1至30之整數、5至45之整數或5至30之整數。
同時,在根據本發明之實施例之嵌段共聚物中,以該嵌段共聚物之總重量計,該親水性第一嵌段之含量可為1至99重量%、1至80重量%或20至60重量%。具體地,該親水性第一嵌段之含量可為,但不限於,20至55重量%、25至60重量%、25至55重量%、25至50重量%、30至55重量%、30至50重量%、30至45重量%、35至50重量%或35至45重量%。此外,以該嵌段共聚物之總重量計,該疏水性第二嵌段之含量可為1至99重量%、10至90重量%或40至80重量%,具體地含量可為40至75重量%、45至80重量%、45至75重量%、45至70重量%、50至75重量%、50至70重量%、50至65重量%、55至70重量%或55至65重量%。另一方面,以該嵌段共聚物之總重量計,該能夠特異性結合至硫醇之官能基之含量可為0.01至10重量%或0.01至5重量%,具體地含量可為0.05至5重量%、0.1至5重量%、0.5至5重量%或1至4重量%。
例如,在根據本發明之實施例之嵌段共聚物中,以該嵌段共聚物之總重量計,聚(醚)或以式1表示的單元作為親水性第一嵌段之含量可為1至99重量%、1至80重量%或20至60重量%,具體地含量可為20至55重量%、25至60重量%、25至55重量%、25至50重量%、30至55重量%、30至50重量%、30至45重量%、35至50重量%或35至45重量%。在根據該實施例之嵌段共聚物中,以該嵌段共聚物之總重量計,聚(胺酯)或以式2表示的單元作為疏水性第二嵌段之含量可為1至99重量%、10至90重量%或40至80重量%,具體地含量可為40至75重量%、45至80重量%、45至75重量%、45至70重量%、50至75重量%、50至70重量%、50至65重量%、55至70重量%或55至65重量%。此外,在根據該實施例之嵌段共聚物中,以該嵌段共聚物之總重量計,作為能夠特異性結合至硫醇之官能基之二硫化物、順丁烯二亞醯胺基團、烯基基團或炔基基團之含量可為0.01至10重量%或0.01至5重量%,具體地含量可為0.05至5重量%、0.1至5重量%、0.5至5重量%或1至4重量%。
此外,在根據本發明之實施例之嵌段共聚物中所含的親水性第一嵌段中,以該親水性第一嵌段之總重量計,聚(醚)或以式1表示的單元之含量可為10至100重量%,具體地含量可為30至100重量%、50至100重量%、60至100重量%、70至100重量%、80至100重量%或90至100重量%。
另一方面,在根據本發明之實施例之嵌段共聚物中所含的疏水性第二嵌段中,以該疏水性第二嵌段之總重量計,聚(胺酯)或以式2表示的單元之含量可為10至100重量%,具體地含量可為30至100重量%、50至100重量%、60至100重量%、70至100重量%、80至100重量%或90至100重量%。
同時,在根據本發明之實施例之嵌段共聚物中,該親水性第一嵌段之總重量對該疏水性第二嵌段之總重量之比可為(1:20)至(20:1),具體地可為(1:10)至(10:1)、(1:10)至(5:1) 、(1:5)至(5:1) 、(1:5)至(3:1) 、(1:5)至(2:1)或(1:5)至(1:1)。
此外,根據本發明之一實施例之嵌段共聚物可為包括一個親水性嵌段及一個疏水性嵌段之雙嵌段共聚物,或可為包括二或更多個親水性嵌段或疏水性嵌段之三、四或五嵌段共聚物。例如,該嵌段共聚物可具有親水性第一嵌段-疏水性第二嵌段之結構,或具有親水性第一嵌段-疏水性第二嵌段-親水性第一嵌段之結構或疏水性第二嵌段-親水性第一嵌段-疏水性第二嵌段之結構。
另一方面,在根據本發明之實施例之嵌段共聚物中,該能夠特異性結合至硫醇之官能基可直接或透過一連接子結合至該嵌段共聚物之主鏈、側鏈或終端或其組合。具體地,該能夠特異性結合至硫醇之官能基可透過一連接子結合至該嵌段共聚物之終端,例如,作為親水性第一嵌段之聚(醚)的醚基團,或作為疏水性第二嵌段之聚(胺酯)的胺或酯基團。
根據本發明之實施例之嵌段共聚物可具有1,000至50,000Da之總分子量,具體地具有2,000至45,000Da、3,000至40,000Da、4,000至30,000Da或5,000至20,000Da之總分子量。
在本發明之另一態樣中,提供一種奈米粒子,其包含上述的嵌段共聚物。
在本發明之一實施例中,該嵌段共聚物可透過疏水性嵌段的自組裝形成具有微胞結構之奈米粒子,及包括一親水性嵌段及一疏水性嵌段二者,以便該疏水性嵌段能夠在受試者或水中自組裝形成核,同時該親水性嵌段能夠形成與水接觸之表面。該微胞是在某濃度或較高濃度下聚合的分子之集合體,且可意指其中兩親分子集合成均勻大小與形狀的結構體。該奈米粒子或微胞可具有各種形狀,如球體、橢球體、圓柱體、環及薄片。
此外,在本發明之又另一態樣中,提供一種藥物遞輸載具,其包含上述的奈米粒子及一藥物。該奈米粒子可具有嵌段共聚物形成的微胞結構,且可在由疏水性嵌段集合形成的微胞之核中攜帶一疏水性藥物。
該藥物遞輸載具可具有50至1,000nm之平均粒徑,更具體地可具有100至200nm之平均粒徑。然而,本發明不限於此。例如,在該藥物遞輸載具中含有多柔比星(doxorubicin)之情況下,該藥物遞輸載具在中性pH下可具有20至400nm之平均粒徑,更具體地可具有100至200nm之平均粒徑。然而,本發明不限於此。具有該相應範圍的平均粒徑之藥物遞輸載具,可在投與至受試者及流經血流之同時容易地附著於細胞表面,且其等之奈米粒子結構或微胞結構不會破掉或降解。
在此,該藥物沒有限制,只要該藥物具有能夠被攜帶在包括上述嵌段共聚物之奈米粒子的內核上之親水性/疏水性特性即可。此一藥物可為疏水性或弱親水性的,例如在室溫下水中可具有20mg/mL或更低的溶解度。在此,該藥物可選自,但不限於,抗癌劑、抗增生或化學治療藥物、止痛劑、抗發炎劑、抗寄生蟲劑、抗心律不整劑、抗細菌劑、抗病毒劑、抗凝血劑、抗憂鬱劑、抗糖尿病藥、抗癲癇劑、抗真菌劑、抗痛風劑、抗高血壓劑、抗瘧疾藥、抗偏頭痛藥、抗毒蕈鹼劑、抗腫瘤劑、抗勃起障礙劑、免疫抑制劑、抗原蟲藥、抗甲狀腺劑、抗焦慮劑、鎮靜劑、催眠藥、精神安定劑、β-阻斷劑、強心劑、皮質類固醇、利尿劑、抗帕金森氏病劑、胃腸藥、組織胺受體拮抗劑、去角質劑、脂質調節劑、心絞痛藥物、Cox-2抑制劑、白三烯抑制劑、巨環內酯、肌肉鬆弛劑、營養素、成癮性鎮痛藥、蛋白酶抑制劑、性荷爾蒙、興奮劑、肌肉鬆弛劑、抗滲透劑、抗肥胖藥、認知增強劑、尿失禁藥物、良性前列腺藥物、必需脂肪酸、非必需脂肪酸及此等之組合。
例如,該藥物可為疏水性或弱親水性抗癌藥,及可包括多柔比星、順鉑、依托泊苷(etoposide)、紫杉醇、歐洲紫杉醇(docetaxel)、喜樹鹼、鬼臼毒素、環磷醯胺、放線菌素、胺甲喋呤、沙利竇邁、厄洛替尼(erlotinib)、艾瑞沙、喜樹鹼、泰莫西芬(tamoxifen)、阿那曲唑(anastrozole)、氟他胺(flutamide)、唑來膦酸(zoledronate)、長春新鹼、視網酸、氯芥苯丁酸、長春鹼、強體松、睪固酮、伊布洛芬、萘普生(naproxen)、吲哚美洒辛(indomethacin)、丁二苯吡唑二酮、地塞松(dexamethasone)、塞來昔布(celecoxib)、伐地昔布(valdecoxib)、尼美舒利(nimesulide)、皮質類固醇或其組合。
該藥物遞輸載具可包括非自然產生的載體。此外,該藥物遞輸載具可進一步包括一生物活性物質,從而在治療與癌症相關疾病中表現出更高的作用。此一生物活性物質意指用於疾病的治療、癒合、預防、診斷等等之物質,其之例子可包括具有醫療功能之細胞、蛋白或胜肽,如生長因子及荷爾蒙、核酸、胞外基質及藥物。
該藥物遞輸載具上所攜帶作為生物活性物質的藥物之例子,可包括抗生素、抗發炎劑、抗病毒劑及抗細菌劑。該抗生素之例子可為選自下列之抗生素:四環素、米諾四環素(minocycline)、去氧羥四環素、氧氟沙星(ofloxacin)、左旋氧氟沙星、塞普沙辛(ciprofloxacin)、克拉黴素、紅黴素、頭孢可若(cefaclor)、頭孢噻肟(cefotaxime)、亞胺培南(imipenem)、青黴素、正大黴素、鏈黴素、萬古黴素等等之衍生物及混合物。該抗發炎劑之例子可為選自下列之抗發炎劑:吲哚美洒辛、伊布洛芬、可多普洛菲(ketoprofen)、匹洛西卡(piroxicam)、氟白普洛芬(flurbiprofen)、雙氯芬酸(diclofenac)等等之衍生物及混合物。該抗病毒劑之例子可為選自下列之抗病毒劑:無環鳥苷、Robavin等等之衍生物及混合物。該抗細菌劑之例子可為選自下列之抗細菌劑:酮康唑(ketoconazole)、艾妥可那唑(itraconazole)、氟康那唑(fluconazole)、雙性黴素-B、灰黃黴素等等之衍生物及混合物。
此外,可以攜帶或結合在該藥物遞輸載具上並遞送至生物體的蛋白質或胜肽之例子,可為各種用於治療或預防疾病之目的之生物活性肽,如荷爾蒙、細胞激素、酵素、抗體、生長因子、轉錄調節因子、血液因子、疫苗、結構蛋白、配體蛋白、多醣類及受體、細胞表面抗原及受體拮抗劑,及其衍生物和類似物。具體地,該蛋白或胜肽之例子可為骨生長因子、肝生長荷爾蒙、生長荷爾蒙釋放荷爾蒙及胜肽、干擾素及干擾素受體(例如,干擾素-α、-β及-γ;可溶性第I型干擾素受體等等)、顆粒性白血球聚落刺激因子(G-CSFs)、顆粒性白血球-巨噬細胞聚落刺激因子(GM-CSFs)、類升糖素胜肽(GLP-1等等)、G蛋白偶聯受體、介白素(例如,介白素-1、-2、-3、-4、-5、-6、-7、-8、-9等等)及介白素受體(例如,IL-1受體、IL-4受體等等)、酵素(例如,葡萄糖腦苷酶、艾杜糖醛酸-2-硫酯酶、α-半乳糖苷酶-A、半乳糖苷酶α及β、α-L-艾杜糖醛酸酶、幾丁質酶、丁醯膽鹼脂酶、脂酶、麩胺酸去羧酶、依米苷酶(imiglucerase)、尿酸酶、血小板活化因子乙醯水解酶、中性胜肽內切酶、髓過氧化酶等等)、介白素及細胞激素結合蛋白(例如,IL-18bp、TNF-結合蛋白等等)、巨噬細胞活化劑、巨噬細胞肽、B細胞因子、T細胞因子、蛋白A、過敏抑制劑、腫瘤壞死因子(TNF)α抑制劑、細胞壞死糖蛋白、免疫毒素、淋巴毒素、腫瘤壞死因子、腫瘤抑制劑、轉移生長因子、α-1抗胰蛋白酶、白蛋白、α-乳白蛋白、脂蛋白E、紅血球生成素、高糖化紅血球生成素、血管生成素、血紅素、凝血酶、凝血酶受體活化肽、凝血酶調節素、血液因子、血液因子a、血液因子XIII、纖維蛋白溶酶原活化劑、纖維蛋白結合肽、尿激酶、鏈激酶、水蛭素、蛋白C、C反應蛋白、腎素抑制劑、膠原酶抑制劑、過氧化物歧化酶、瘦體素、血小板衍生生長因子、上皮生長因子、表皮生長因子、血管抑制素、血管收縮素、骨原生長因子、骨形態發生蛋白、抑鈣素、胰島素、心房肽(atriopeptin)、軟骨誘發物、依降鈣素(elcatonin)、結締組織活化劑、組織因子路徑抑制物、促濾泡素、黃體素形成激素、促黃體激素釋放激素、神經生長因子(例如,神經生長因子、睫狀神經營養因子、軸突生長因-1 (axogenesis factor-1)、腦利鈉肽(brain-natriuretic peptide)、神經膠細胞衍生神經滋養因子、軸突生長誘向因子(netrin)、嗜中性球抑制因子、神經滋養因子及神經營養因子(neurturin))、副甲狀腺素、鬆弛素、分泌素、體介素、似胰島素生長因子、腎上腺皮質素、升糖素、膽囊收縮素、胰多肽、胃泌素釋放肽、促腎上腺素釋放因子、促甲狀腺素、自分泌運動因子(autotaxin)、乳鐵蛋白、肌肉生長抑制素、受體(例如TNFR (P75)、TNFR (P55)、IL-1受體、VEGF受體、B細胞活化因子受體等等)、受體拮抗劑(例如,IL1-Ra)、細胞表面抗原(例如,CD 2、3、4、5、7、11a、11b、18、19、20、23、25、33、38、40、45、69)、單株抗體、多株抗體、抗體片段(例如,scFv、Fab、Fab'、F(ab')2及Fd)及病毒來源疫苗抗原。
可以物理方式攜帶在該藥物遞輸載具上或以化學方式結合至該藥物遞輸載具並遞輸至生物體內之核酸的例子,可為DNA、RNA、PNA及寡核苷酸。
可以物理方式與一生物活性物質一起攜帶在該藥物遞輸載具上並遞輸至生物體內之細胞的例子,可為幹細胞、纖維母細胞、血管內皮細胞、平滑肌細胞、神經元、軟骨細胞、骨細胞、皮膚細胞及許旺細胞。
根據本發明之實施例之藥物遞輸載具可具有25至400nm或50至200nm之平均直徑。例如,在通過將多柔比星作為藥物攜帶在包含以式4或5表示之嵌段共聚物的奈米粒子上來形成藥物遞輸載具之情況下,該奈米粒子可具有100至200nm之平均直徑,且以該奈米粒子之總重量計,多柔比星之包含率可高達5至10重量%。
將參考圖1更詳細的說明根據本發明之實施例之藥物遞輸載具的示範作用。如圖1所示,包括實施例之嵌段共聚物且其上攜帶抗癌藥物之藥物遞輸載具(呈微胞形式),透過該嵌段共聚物中所包含之能夠特異性結合至硫醇基團之官能基(未示出)而附著於自然殺手細胞之表面,如此增強了該免疫細胞;及在該增強的免疫細胞辨識且開始攻擊癌細胞的情況下,其等之周圍環境變成酸性並導致該藥物遞輸載具經歷結構改變,從而該微胞上所攜帶的抗癌藥物被釋出而引起該癌細胞死亡。
如此,根據本發明之實施例之藥物遞輸載具可準確地將高毒性抗癌藥物遞輸至癌細胞附近,使得能夠利用具有很強的抗癌作用,但由於其非特異性毒性所引起的嚴重副作用而受限之化學抗癌藥物,還容許發揮最大抗癌療效及能力之作用。此外,雖然根據本發明之實施例之藥物遞輸載具附著於免疫細胞且在血液中流動,但由於藥物的釋出會因其周圍中性環境而受到抑制,故能夠避免由其所攜帶的抗癌藥物所引起的全身性毒性。
在本發明之又再另一態樣中,提供一種通過使包含上述嵌段共聚物及一藥物之一藥物遞輸載具與一免疫細胞之表面結合而獲得之修飾細胞。該修飾細胞可進一步包括非自然產生的載體和/或如上所述的生物活性物質。
此外,該免疫細胞可選自例如T細胞、自然殺手細胞、樹突狀細胞(DCs)、巨噬細胞、微膠質細胞及此等之組合。此外,該免疫細胞之表面上可包括硫醇基團,因此可在結合至該實施例之嵌段共聚物之情況下具有增強的作用,此結合是透過該嵌段共聚物中所包含之一能夠特異性結合至硫醇基團之官能基而產生。具體地,與T細胞及自然殺手細胞一樣,該免疫細胞可形成免疫突觸並釋出溶解顆粒而形成毒殺細胞的作用。此外,該免疫細胞可具有在免疫突觸附近被酸化,同時攻擊癌細胞的特徵。由於免疫細胞之此特徵,因應癌細胞附近的酸性環境,該實施例之嵌段共聚物之疏水性第二嵌段可被分解或變成陽離子型,從而釋出該嵌段共聚物上所攜帶的藥物。
在本發明之又再另一態樣中,提供一種用於抗癌用途的藥學組成物,其包含上述的嵌段共聚物及一抗癌藥物。此外,在本發明之又再另一態樣中,提供一種用於抗癌用途或預防或治療感染的藥學組成物,其包含上述的嵌段共聚物、一藥物及一免疫細胞。
該癌症可選自結腸癌、肺癌、非小細胞肺癌、骨癌、胰臟癌、皮膚癌、頭癌、子宮頸癌、皮膚黑色素瘤、眼內黑色素瘤、子宮癌、卵巢癌、直腸癌、胃癌、肛周癌、乳癌、輸卵管癌、子宮內膜癌、子宮頸癌、陰道癌、外陰癌、霍奇金氏病、食道癌、小腸癌、內分泌腺癌、甲狀腺癌、副甲狀腺癌、腎上腺癌、軟組織肉瘤、尿道癌、陰莖癌、前列腺癌、慢性白血病、急性白血病、淋巴細胞淋巴瘤、膀胱癌、腎癌、輸尿管癌、腎細胞癌、腎盂癌及中樞神經系統(CNS)腫瘤。然而,該癌症不特別限於此。
在本發明之一實施例中,該藥學組成物意指針對特定目的投與之組成物。就本發明而言,本發明之藥學組成物可用於預防或治療癌症疾病或病症,或感染之目的,且可包括其中涉及的蛋白質及一藥學上可接受的載體、賦形劑或稀釋劑。此外,本發明之藥學組成物可進一步包括非自然產生的載體和/或如上所述的生物活性物質。
該藥學上可接受的載體或賦形劑可為政府管制部門核准的,或政府核准藥典或其它公認的藥典中用於脊椎動物,更特定地人中所列出的。
為適合腸胃外投與,該藥學組成物可製成具有油性或水性載體之懸液劑、溶液劑或乳劑之形式,可製成固體或半固體之形式,及可包括諸如助懸劑、安定劑、助溶劑和/或分散劑之調配劑。此形式可為無菌的且可為液體。該藥學組成物在製備及儲存條件下可為安定的,且可保存防止微生物如細菌或真菌的污染。選擇性地,該藥學組成物可為在使用前用適合的載體重建之無菌粉末形式。該藥學組成物可為單一劑量形式、微針貼片、安瓿或其它單一劑量容器或多劑量容器。選擇性地,該藥學組成物可以凍乾(冷凍乾燥)之狀態保存,其僅需要在即將使用之前添加無菌液態載體,例如,注射用水。即時注射溶液及懸液劑可用無菌粉末、顆粒或錠劑配製成。
在一些非限制性實施例中,本發明之藥學組成物可調配成液體,或包含在液體中呈微球之形式。在某些非限制性實施例中,本發明之藥學組成物包括濃度0.001至100,000U/kg之藥學上可接受的化合物和/或混合物。此外,在某些非限制性實施例中,適於本發明之藥學組成物之賦形劑包括防腐劑、助懸劑、安定劑、染劑、緩衝劑、抗細菌劑、抗真菌劑及等張劑,諸如糖或氯化鈉。該安定劑意指為了增加其儲存夀命而任擇地在本發明之藥學組成物中使用的化合物。在一些非限制性實施例,該安定劑可為糖、胺基酸、化合物或聚合物。該藥學組成物可包括一或多種藥學上可接受的載體。該載體可為溶劑或分散介質。該藥學上可接受的載體之非限制性例子,包括水、食鹽水、乙醇、多元醇(例如,甘油、丙二醇及液態聚乙二醇)、油及其適當的混合物。此外,腸胃外配方可為經滅菌的。滅菌技術之非限制性例子包括通過截留細菌的過濾器過濾、最終滅菌、摻入滅菌製劑、輻射滅菌、滅菌氣體照射、加熱、真空乾燥及凍乾。
在本發明之一實施例中,術語"投藥"意指以任何適合的方法將本發明之化合物導入病患中。本發明之組成物可透過任何一般途徑投與,只要該途徑容許本發明之組成物達到標的組織即可。本發明之組成物可經口、腹膜內、靜脈內、肌肉內、皮下、真皮內、鼻內、肺內、直腸內、腔內或鞘內投與。然而,在該藥學組成物包括根據本發明之藥物遞輸載具的情況下,因為該藥物遞輸載具必須附著於細胞,以便同時進行化學療法及免疫療法,所以該藥學組成物較佳地係腸胃外投與,且可以注射劑之形式投與。
在本發明之又再另一態樣中,提供一種用於預防或治療癌症疾病或病症之方法,其包含對一受試者投與上述的嵌段共聚物及一抗癌藥物。該預防或治療方法可通過對該受試者同時投與一藥學上有效量之該包括上述嵌段共聚物之藥學組成物及一藥物來進行。選擇性地,該預防或治療方法可通過在一時間間隔對該受試者投與該嵌段共聚物及該藥物來進行。
在本發明之又再另一態樣中,提供一種用於預防或治療癌症疾病或病症或感染之方法,其包含投與上述嵌段共聚物、一藥物及一免疫細胞。該預防或治療方法可包含對一受試者同時投與藥學上有效量之該包括上述的嵌段共聚物之藥學組成物、一藥物及一免疫細胞。選擇性地,該預防或治療方法可通過在一時間間隔對該受試者投與該嵌段共聚物、該藥物及該免疫細胞來進行。
在本發明中,有效量可根據各種因素調整,包括癌症疾病之類型、疾病嚴重度、該組成物中活性成分及其它成份的類型與數量、配方之類型及病患的年齡、體重、總體健康狀況、性別及飲食、投藥時間、投藥途徑及化合物之分泌速率、治療期間及同時使用的藥物。
在本發明中,術語"受試者"可指人類及包括乳牛、馬、綿羊、豬、山羊、駱駝、羚羊、狗等等之哺乳動物,且可指人類除外的哺乳動物。
另一方面,在本發明之又再另一態樣中,提供一種用於製備上述嵌段共聚物的方法。
用於製備該嵌段共聚物的方法可包含步驟:S1)使包括一親水性第一嵌段之一親水性聚合物與包括一疏水性第二嵌段之一疏水性聚合物反應;及S2)使該親水性聚合物或該疏水性聚合物與一包括能夠特異性結合至硫醇基團之官能團的化合物反應。該製備方法之各別步驟的順序可改變。
步驟S1可通過包含下列來進行:將一第一誘導官能基導入該親水性聚合物及該疏水性聚合物之一個中之步驟;及使其中導入該第一誘導官能基之該親水性聚合物及該疏水性聚合物中之一個,與該疏水性聚合物及該親水性聚合物之另一個反應之步驟。
此外,步驟S2可通過包含下列來進行:將一第二誘導官能基導入該親水性聚合物及該疏水性聚合物之一個中之步驟;及使其中導入該第二誘導官能基之該親水性聚合物及該疏水性聚合物中之一個,與一包括能夠特異性結合至硫醇基團之官能基的化合物反應之步驟。在此,導入該第二誘導官能基之步驟可在步驟S1之前進行。此外,步驟S2可進一步包括將一第三誘導官能基導入該包括能夠特異性結合至硫醇基團之官能基的化合物之步驟 。
具體地,用於製備根據該實施例之嵌段共聚物之方法可包含步驟:S1-1)將一第一誘導官能基及一第二誘導官能基導入包括一親水性第一嵌段之一親水性聚合物中;S1-2)使包括該第一誘導官能基及該第二誘導官能基之該親水性聚合物,與包括一疏水性第二嵌段之一疏水性聚合物反應,其中該反應透過該第一誘導官能基發生;S2-1)將一第三誘導官能基導入一包括能夠特異性結合至硫醇基團之官能基的化合物中;及S2-2)使該親水性聚合物、該疏水性聚合物或其組合,與其中導入該第三誘導官能基之該包括能夠特異性結合至硫醇基團之官能基的化合物反應,其中該反應透過該三誘導官能基發生。該製備方法之各別步驟的順序可改變。例如,步驟S2-1可在步驟S1-1之前進行。
該親水性聚合物意指包括上述親水性第一嵌段且為親水性之聚合物。該親水性聚合物之數量平均分子量(Mn)沒有特別限制,可為500至5,000g/mol,具體地1,000至3,000g/mol或1,500至2,500g/mol。在該親水性聚合物之數量平均分子量小於500g/mol或大於5,000g/mol之情況下,該親水性聚合物可能很難透過在特定pH條件下由親水性/疏水性平衡所引起的自組裝而形成微胞;或即使形成了微胞,但該微胞可能會因溶於水中而破掉或者沈澱。該親水性聚合物可為例如聚乙二醇類之聚合物。
該疏水性聚合物意指包括上述疏水性第二嵌段且為疏水性之聚合物。該疏水性聚合物之數量平均分子量(Mn)同樣地沒有特別限制,可為1,500至27,000g/mol、3,000至13,000g/mol、3,000至10,000g/mol或4,500至8,500g/mol。該疏水性聚合物可為例如聚(胺酯)、聚(醯胺基胺)或聚(胺酯)(醯胺基胺)。因為此等聚合物具有一特性,即由於其中存在胺基團,其等於水中之溶解度會隨著pH條件變化,所以微胞結構之形成或破掉可隨著pH條件變化。該疏水性聚合物可根據業界一般已知的方法製備,及可通過例如麥可反應,進行雙丙烯酸酯化合物或雙丙烯醯胺化合物與胺類化合物的聚合反應而獲得。
該包括能夠特異性結合至硫醇基團之官能基的化合物,意指包括上述之能夠特異性結合至硫醇基團之官能基的化合物。具體地,該包括能夠特異性結合至硫醇基團之官能基的化合物可為二硫化物、順丁烯二亞醯胺、烯類、炔類等等。更具體地,該化合物可為順丁烯二亞醯胺或順丁烯二亞醯胺炔,但不特別限於此。
該第一誘導官能基意指一種用於導入親水性聚合物或疏水性聚合物,以使該親水性聚合物及該疏水性聚合物彼此連接之官能基,且此第一誘導官能基可適當地依照該親水性聚合物或該疏水性聚合物中所存在的官能基類型作選擇。例如,在該親水性聚合物包括羥基基團及該疏水性聚合物包括胺基團之情況下,可於該親水性聚合物之該羥基基團的位置處導入作為該第一誘導官能基之烯基基團、炔基基團或丙烯酸酯基團,使該第一誘導官能基能與該疏水性聚合物的胺基團反應,其中此一第一誘導官能基使得該親水性聚合物與該疏水性聚合物能夠經由游離基聚合反應而連接/共聚合在一起。此外,考慮溶劑之選擇、聚合反應溫度等等,可輕易地將該第一誘導官能基如烯基基團、炔基基團或丙烯酸酯基團,導入該親水性聚合物與該疏水性聚合物中之該親水性聚合物。
該第二誘導官能基意指一種用於導入親水性聚合物或疏水性聚合物,以使該親水性聚合物或該疏水性聚合物連接至該包括能夠特異性結合至硫醇基團之官能基的化合物之官能基,且此第二誘導官能基可依照該親水性聚合物或該疏水性聚合物中所存在的官能基類型及該能夠特異性結合至硫醇基團之官能基的類型作選擇。例如,在該親水性聚合物包括羥基基團之情況下,可將作為該第二誘導官能基之疊氮基團導入該親水性聚合物之該羥基基團的位置。
該第三誘導官能基意指一種官能基,其用於導入該包含能夠特異性結合至硫醇基團之官能基的化合物,以使該親水性聚合物或該疏水性聚合物連接至該包括能夠特異性結合至硫醇基團之官能基的化合物,且此第三誘導官能基可依照該親水性聚合物或該疏水性聚合中所存在的官能基類型及該能夠特異性結合至硫醇基團之官能基的類型作選擇。例如,在該親水性聚合物或該疏水性聚合物中存在疊氮基團之情況下,可將作為該第三誘導官能基之烯基基團、炔基基團、丙烯酸酯基團或二硫化物基團導入該包括能夠特異性結合至硫醇基團之官能基的化合物中。其中,該烯基基團及該疊氮基團具有容許透過簡單的方法使反應很容易進行之優點,該簡單的方法之反應條件非常簡單,像是透過點擊化學(click chemistry)進行反應。然而,本發明不特別限於此。
在步驟S1中,該親水性聚合物對該疏水性聚合物之反應重量比可為(1:20)至(20:1),具體地(1:10)至(10:1)、(1:10)至(5:1)、(1:5)至(5:1)、(1:5)至(3:1)、(1:5)至(2:1)或(1:5)至(1:1)。在該反應重量比不在該範圍內之情況下,最終的嵌段共聚物中疏水性嵌段太少,可能會妨礙微胞的形成且導致該親水性聚合物與該疏水性聚合物呈現溶解的狀態,或該疏水性嵌段太多,可能會妨礙微胞的形成且導致該親水性聚合物與該疏水性聚合物沈澱。此外,該親水性聚合物對該疏水性聚合物之反應莫耳比可為(1:5)至(5:1),具體地(1:4) 至(4:1)、(1:3) 至(3:1)、(1:2) 至(3:1)或(1:1)至(3:1)。藉由調節該反應莫耳比,能夠形成各種嵌段形式,包括雙嵌段共聚物、三嵌段共聚物或更高級的嵌段共聚物。
根據該製備方法製得之共聚物的分子量範圍沒有特別限制,可為1,000至50,000g/mol,具體地2,000至45,000g/mol、3,000至40,000g/mol、4,000至30,000g/mol或5,000至20,000g/mol。在該分子量小於1,000g/mol之情況下,該嵌段共聚物不僅在特定pH下很難形成微胞,且即使形成微胞,該微胞會溶於水中且很容易破掉。此外,在該分子量超過50,000g/mol之情況下,由於親水性/疏水性平衡崩潰,所以在特定pH不會形成微胞且可能會沈澱。
同時,在本發明之又再另一實施例中,提供一種用於製備包括上述嵌段共聚物之奈米粒子的方法,其包含製備該嵌段共聚物之步驟;及將該嵌段共聚物、一溶劑及一水溶液混合以形成一奈米粒子之步驟。例如,該奈米粒子形成步驟之進行,首先通過將該嵌段共聚物與該溶劑混合,然後使該混合物與該水溶液混合,如此形成一微胞。
在該溶劑方面,可使用甲苯、氯仿、四氫呋喃、二甲基亞碸、二甲基甲醯胺、二氯甲烷等等。此外,在該微胞形成步驟中,可單獨或組合使用如攪拌、加熱、超音波掃描、使用乳化作用之溶劑蒸發、基質形成或使用有機溶劑之透析之方法。
在本發明之又再另一實施例中,提供一種用於製備包括上述嵌段共聚物及一藥物之藥物遞輸載具的方法,其包含:製備該嵌段共聚物之步驟;及將該嵌段共聚物與該藥物混合以形成一藥物遞輸載具之步驟。例如,該藥物遞輸載具形成步驟之進行,可通過首先將該嵌段共聚物、該藥物及一溶劑混合以製得一混合物,然後於該混合物中加入一水溶液,以形成一微胞。該溶劑及該微胞形成方法如上所述。
此外,在本發明之又再另一實施例中,提供一種用於產生包括上述藥物遞輸載具及一免疫細胞之修飾細胞的方法,其包含:製備上述嵌段共聚物之步驟;及將該嵌段共聚物、一藥物及一免疫細胞混合以形成一修飾細胞之步驟。例如,該修飾細胞形成步驟之進行,可通過形成包括該嵌段共聚物與該藥物之一奈米粒子,然後使該奈米粒子與該免疫細胞混合。該修飾細胞可通過該免疫細胞表面上所存在的硫醇基團與一會特異性結合至該奈米粒子之表面上露出的硫醇之官能基之結合而形成。該溶劑及該奈米粒子形成方法如上所述。用於本發明之模式
下文中,提供較佳實施例幫助對本發明的理解。然而,對於熟悉此技術之人士顯而易見的是,下列範例僅用於例示說明本發明,且在本發明之技術思想範疇內可製得各種變化及修飾;亦很明顯的是,此變化及修飾附屬於所附的申請專利範圍。範例1 ,嵌段共聚物及藥物遞輸載具的合成及其特徵的評估 範例1.1 ,嵌段共聚物中包含親水性第一嵌段的親水性聚合物之合成
為合成包括親水性第一嵌段、疏水性第二嵌段及能夠特異性結合至硫醇之官能基的嵌段共聚物,首先用與圖2中相同的方法合成丙烯酸酯-PEG-N3
,其作為包括親水性嵌段之親水性聚合物。首先,將具有分子量2,000Da 之PEG (10.000g;5.0mmol)溶於160mL冷CH2
Cl2
中,然後加入溶於20mL H2
Cl2
中之Ag2
O (1.738g;7.5mmol)、KI (0.332g;2.0mmol)及TsCl (1g;5.25mmol)並激烈攪拌。令此反應在氮環境下進行2個小時,然後利用矽膠過濾出反應產物。除去該反應產物中之溶劑,然後再結晶而獲得純甲苯磺酸酯-PEG-OH (化合物1)。此反應之產率測定為81%。隨後,在40mL DMF溶劑下之甲苯磺酸酯-PEG-OH (化合物1) (4.000g;1.86mmol)中加入NaN3
(0.605g;9.3mmol),於65℃下進行攪拌18個小時。將溫度降低至室溫,然後於真空中除去DMF。將產物溶於CH2
Cl2
中,然後通過矽膠,獲得HO-PEG-N3
(化合物2)。此產物之產率測定為76%。
最後,將因此獲得的HO-PEG-N3
(化合物2) (2.0g,0.980mmol)溶於15mL之冷CH2
Cl2
與TEA (0.397mL;3.980 mmol)中。在氮環境下,於此混合物中慢慢地逐滴加入氯化丙烯醯基(0.266mL;2.940mmol)溶於15mL CH2
Cl2
中之溶液。在全部添加完成後,在氮環境下攪拌反應產物24個小時,使該反應產物慢慢地冷卻至室溫。在真空中除去溶劑,然後將殘留的反應產物再次溶於THF溶劑中,以除去Et3
N・HCl鹽。之後,使產物在二乙醚中沈澱,獲得最終產物丙烯酸酯-PEG-N3
(化合物3)。此反應之產率測定為75%。
化合物1至3之1
H NMR (CDCl3
)結果示於圖3中。範例1.2 ,嵌段共聚物中包括疏水性第二嵌段之疏水性聚合物之合成
為繼續合成該嵌段共聚物,以與圖4中所示相同的方法合成具有分子量10,000Da之Mal-PEG-PBAE-PEG-Mal,其作為包括疏水性第二嵌段之疏水性聚合物。
首先,將4,4'-三亞甲基二哌啶(TMDP) (M1,0.542g;2.578mmol)及二丙烯酸-1,6-己二醇酯(HDDA) (M2,0.500g;2.210mmol)溶於10mL無水CH2
Cl2
中。之後,在40℃下進行聚合反應2天,從其中合成出聚(β-胺酯) (PBAE) (化合物4)。化合物4之1
H NMR (CDCl3
)結果示於圖5中。範例1.3 ,嵌段共聚物的合成
之後,將範例1.1中合成的丙烯酸酯-PEG-N3
(化合物3) (0.794g;0.382mmol)溶於2mL無水CH2
Cl2
中,並加至該反應中。使該反應在40℃下進行2天。結果,合成出N3
-PEG-PBAE-PEG-N3
(化合物5),及通過二乙醚沈澱純化。此反應之產率測定為93%。
最後,透過銅介導的點擊化學使炔-順丁烯二亞醯胺(0.032g;0.230mmol)附著於N3
-PEG-PBAE-PEG-N3
(化合物5) (0.500g,0.045mmol)。將二個反應物均溶於10mL具有1-(丙-2-炔基)-1H-吡咯-2,5-二酮(0.008g,0.045mmol)的DMF中,令反應在氮氣注入的環境中進行30分鐘。之後,在氮環境下加入CuBr (0.007g;0.045mmol),且在45℃下進行點擊化學24個小時。之後,使產物通過矽膠,除去銅催化劑並於二乙醚中沈澱,獲得Mal-PEG-PBAE-PEG-Mal共聚物(化合物6)。
化合物5及6之1
H NMR (CDCl3
)結果示於圖5中。範例1.4 ,藥物遞輸載具之形成
為形成包括嵌段共聚物及藥物的藥物遞輸載具(ReMi),將100mg範例1.3中合成的Mal-PEG-PBAE-PEG-Mal共聚物(化合物6)溶於4mL DMSO中,於其中加入50μg/mL濃度的抗癌藥物,多柔比星(DOX)。隨後,在激烈攪拌該混合物之同時逐滴加入20mL的蒸餾水,之後再進行攪拌30分鐘。透過3,500Da大小的透析膜,以蒸餾水透析此溶液。將因此獲得的ReMi凍乾並儲存。範例1.5 ,螢光隨著酸度增加而增加之指示珠的合成
將胺修飾的聚苯乙烯珠(200nm,5.68×1011
粒子)及琥珀醯亞胺基3-(2-吡啶二硫基)丙酸酯(SPDP) (1.16mg;3.7248μmol)溶於5mL之DMSO中,然後使反應在室溫振盪下進行30分鐘。之後,加入10mM的三 (2-羧乙基)膦(TCEP) (1.43mg;5μmol)且在室溫下攪拌30分鐘。之後,加入pHrodo-順丁烯二亞醯胺磷(0.6mg,0.65μmol)且在室溫、暗條件下攪拌1個小時。然後,加入NHS-PEG-順丁烯二亞醯胺(5000Da;31.04mg;6.208μmol)以除去殘留的胺殘基,令反應在室溫、暗條件下進行24個小時。將因此合成的珠在4000rpm下離心2分鐘,然後除去上清液,獲得指示珠。範例1.6 ,藥物遞輸載具之特徵分析
為了鑑定範例1.4中所形成的藥物遞輸載具(ReMi)是否具有隨著pH變化的刺激反應性,用動態光散射(DLS)計算在pH 11、pH 7.5及pH 5.5條件下以及在pH 7.5下放置3天之平均水合尺寸分佈。結果示於圖6中。
如圖6所示,鑑定出ReMi僅在酸性條件下被分解,因此表現出水合尺寸縮小,及從放置3天後水合尺寸仍維持之觀點來看,鑑定出ReMi在正常條件下係安定的。此結果亦通過圖7中穿透式電子顯微鏡影像的鑑定。範例1.7 ,藥物遞輸載具中藥物釋出控制之特徵分析
為了鑑定範例1.4中所形成的藥物遞輸載具(ReMi)是否表現出隨著pH變化而改變藥物釋出行為,通過測量在多比柔星(DOX)之特徵螢光波長(ex = 495 nm;ex = 595 nm)下之螢光,檢核ReMi之藥物釋出行為與pH之關係。將ReMi分別投與至設定至pH 7.5及pH 5.5之水溶液條件,然後通過螢光光度計測量透過透析排出的DOX之螢光強度。結果示於圖8中。
從圖8鑑定出,在酸性環境下48個小時內,從ReMi釋出70%的藥物,而在中性條件下相同時間期間,僅約20%的藥物釋出至外面。範例1.8 ,藥物遞輸載具之細胞附著的特徵分析
為了鑑定範例1.4中所形成的藥物遞輸載具(ReMi)是否可成功地附著於免疫細胞,將ReMi與自然殺手細胞(NK細胞)一起培育,30分鐘後收集細胞,製備顯微鏡樣本。用螢光顯微鏡觀察如此製得的顯微鏡樣本。結果示於圖9中。
如圖9所示,鑑定出ReMi成功地附著於免疫細胞之表面。範例2 ,藥物遞輸載具在使用之情況下是否會識別並攻擊癌細胞的鑑定
使範例1.4中所形成的藥物遞輸載具(ReMi)附著於自然殺手細胞之表面,然後連續拍攝螢光顯微影像4個小時。其影像示於圖10及11中。在此,自然殺手細胞之表面經過根據範例1.5製得的指示珠(其螢光強度隨著酸度增加而增加)之修飾。
如圖10所示,鑑定出在自然殺手細胞攻擊癌細胞之情況下,自然殺手細胞周圍環境的酸度大幅地增加。
如圖11所示,利用螢光顯微鏡觀察其上攜帶抗癌藥物之ReMi 4個小時,結果透過螢光強度的增加鑑定出,當自然殺手細胞開始辨識並攻擊癌細胞時,抗癌藥物,多比柔星,從ReMi釋出。
即,鑑定出在免疫細胞識別並攻擊癌細胞之情況下,免疫細胞周圍的酸度增加,其容許藥物從藥物遞輸載具中釋出。範例3 ,藥物遞輸載具之安定性的評估
透過細胞毒性分析法,分析藥物遞輸載具的安定性。將8,000個A549-LUC細胞或24,000個NK-92MI細胞分配於96孔細胞培養皿中,然後培育1天。之後,於各個孔中加入20μL之攜帶0.3μM多柔比星的ReMi,並培育12個小時。之後,透過MTS細胞毒性分析檢查細胞死亡,結果示於圖12中。
如圖12所示,鑑定出ReMi本身不會傷害癌細胞及自然殺手細胞。範例4 ,藥物遞輸載具增強免疫細胞之抗癌作用的鑑定
透過細胞毒性分析法,鑑定藥物遞輸載具增強免疫細胞之抗癌作用。將8,000個A549-LUC細胞分配於96孔細胞培養皿中,然後培育1天。然後,以每孔1×103
個細胞之密度分配A549-LUC細胞,且將根據表1所示條件的各樣本加至各孔中。進行培育12個小時。然後,透過MTS細胞毒性分析法檢查細胞死亡,結果示於圖13中。在此,圖13所示的結果是將共同投與多比柔星與自然殺手細胞(DOX + NK)之情況下所發揮的抗癌能力設定為100%,及將僅以PBS處理之情況下所發揮的抗癌能力設定為0%所獲得之圖示。所使用的ReMi是範例1.4中所製備之攜帶0.3μM多比柔星的載具,而ReNK意指ReMi附著的自然殺手細胞。
[表1]
樣本名稱 | ReMi 之劑量 | 自然殺手細胞之劑量密度 | DOX 處理濃度 | Ciliobrevin D 處理濃度 |
PBS | - | - | - | - |
DOX | - | - | 0.3 μM | - |
DOX+NK | - | 2.4 × 104 細胞/孔 | 0.3 μM | - |
ReMi | 20 μL | - | 0.3 μM | - |
NK | - | 2.4 × 104 細胞/孔 | - | - |
NK+CD | - | 2.4 × 104 細胞/孔 | - | 100 μM |
ReNK | 20 μL | 2.4 × 104 細胞/孔 | 0.3 μM | - |
ReNK+CD | 20 μL | 2.4 × 104 細胞/孔 | 0.3 μM |
如圖13所示,鑑定出在投與會抑制自然殺手細胞之溶解顆粒的形成之Ciliobrevin D (CD)之情況下(NK + CD或ReNK + CD),自然殺手細胞之總抗癌能力降低。此充分的解釋通過溶解顆粒實現藥物遞輸系統的必要性。另一方面,鑑定出ReNK表現出相對於70%的抗癌能力,其鑑定出同時遞輸抗癌免疫療法及抗癌化學療法是有效的。亦鑑定出,在攜帶藥物之藥物遞輸載具以附著於自然殺手細胞之狀態投與之情況下,能夠同時實現免疫療法及化學療法之藥物遞輸系統,因此表現出提高的抗癌作用。範例5 ,透過動物模型鑑定藥物遞輸載具之抗癌作用
在雌性Balb/c-nu/nu小鼠身上靜脈內接種1×107
細胞/小鼠之A549-LUC細胞。一天後,對各別的實驗組靜脈內注射表2所示條件下之不同的樣本。再一天後,從小鼠身上採取動脈血,利用ELISA測量血漿中之IFN-γ位準。結果示於圖14中。在此,ReNK意指ReMi附著的自然殺手細胞,而所使用的ReMi是範例1.4中所製備之攜帶0.3μM多柔比星的載具。此外,IFN-γ是免疫細胞激素,較高的IFN-γ意指較高的抗癌細胞毒性。
[表2]
樣本名稱 | 自然殺手細胞之劑量密度 | DOX 處理濃度 |
PBS | - | - |
DOX | - | 1 mg/kg |
DOX+NK | 1 × 107 細胞 | 1 mg/kg |
NK | 1 × 107 細胞 | - |
ReNK | 1 × 107 細胞 | 0.65 mg/kg |
如圖14所示,鑑定出在身上已投與癌細胞之小鼠中投與ReNK之情況下,IFN-γ位準顯著地增加,意指自然殺手細胞之細胞毒性積極表現。此外,在這個活體內實驗中,ReNK表現出明顯比NK+DOX優異的結果,與範例4中之活體外的實驗不同,這樣的結果被理解為由於藥物遞輸載具附著於自然殺手細胞,及該自然殺手細胞標靶癌細胞,釋出該藥物之事實。因此,鑑定出將ReMi附著於自然殺手細胞上,以便增強了該自然殺手細胞,從而表現出顯著增加的抗癌作用。範例6 ,透過動物模型鑑定藥物遞輸載具之轉移性致瘤性抑制作用
在雌性Balb/c-nu/nu小鼠身上靜脈內接種1×107
細胞/小鼠之A549-LUC細胞。 一天後,對各別的實驗組靜脈內注射表2所示條件下之不同的樣本,及在投藥後飼養小鼠讓癌生長三個禮拜。之後,在一些小鼠之腹膜內注射螢光素酶,然後安樂死。從其中採集肺,透過活體內影像系統測量A549-LUC之發光,如圖15所示。定量該發光,結果示於圖16中。將一些其它的小鼠麻醉,在麻醉下從其獲得正子放射造影(PET)影像。結果示於圖17中。之後,將小鼠安樂死。從其中取出肺,然後獲得擬體內(ex vivo)正子放射造影(PET)影像。結果示於圖18中。定量圖17及18之影像,結果示於圖19中。
如圖15及16所示,鑑定出投與ReNK的實驗組具有明顯比其它實驗組小的癌,其鑑定出具有優異的轉移性致瘤性抑制作用。
此外,如圖17至19所示,鑑定出投與ReNK的實驗組具有比其它實驗組低的癌細胞發光,其鑑定出該免疫細胞在活體內及擬體內二者之抑制轉移性致瘤性方面,均得到增強。
從範例1至6之結果鑑定出,本發明之藥物遞輸載具以微胞結構之 形式附著於自然殺手細胞之表面,使自然殺手細胞變成具有優異毒殺癌細胞能力之強免疫細胞,且發現此強免疫細胞表現出優異的抗癌作用。
圖1說明在體內投與根據本發明之實施例之嵌段共聚物的情況下,由該嵌段共聚物引起的模擬反應視圖。
圖2說明用於合成根據本發明之實施例之嵌段共聚物中之親水性第一嵌段的反應流程圖。
圖3說明在根據本發明之實施例之嵌段共聚物中之親水性第一嵌段的合成中,中間化合物及最終化合物的1H-NMR光譜。
圖4說明用於合成根據本發明之實施例之嵌段共聚物中之疏水性第二嵌段之反應流程圖。
圖5說明在根據本發明之實施例之嵌段共聚物中之疏水性第二嵌段的合成中,中間化合物及最終化合物的1H-NMR光譜。
圖6說明顯示根據本發明之實施例之藥物遞輸載具取決於pH條件之平均水合尺寸圖表。
圖7說明根據本發明之實施例之藥物遞輸載具取決於pH條件的穿透式電子顯微鏡影像。
圖8說明顯示根據本發明之實施例之藥物遞輸載具取決於pH條件之藥物釋出行為圖表。
圖9說明根據本發明之實施例之藥物遞輸載具附著於細胞的螢光影像。
圖10及11說明根據本發明之實施例之藥物遞輸載具附著於自然殺手細胞及該自然殺手細胞辨識與攻擊癌細胞時所拍攝的螢光影像。
圖12說明評估根據本發明之實施例之藥物遞輸載具之細胞毒性所獲得的結果。
圖13說明顯示根據本發明之實施例之藥物遞輸載具之癌細胞毒殺作用的圖表。
圖14說明在將根據本發明之實施例之藥物遞輸載具投與至動物癌症模型之情況下,通過測量IFN-γ位準所獲得的圖表。
圖15至19說明在將根據本發明之實施例之藥物遞輸載具投與至動物癌症模型之情況下,通過評估該藥物遞輸載具之轉移性致瘤性抑制作用所獲得的結果。
(無)
Claims (13)
- 一種嵌段共聚物,其包含一以式5表示之單元,以及一能夠特異性結合至硫醇之官能基,其經由一連接子連接至該嵌段共聚物的各終端(*):
- 如請求項1之嵌段共聚物,其中該嵌段共聚物具有1,000至50,000Da之一分子量。
- 如請求項1之嵌段共聚物,其中以該嵌段共聚物之總重量計,該能夠特異性結合至硫醇之官能基之含量為0.01至5重量%。
- 如請求項1之嵌段共聚物,其中(p+r)/q是(1:10)至(10:1)。
- 一種奈米粒子,其包含:如請求項1之嵌段共聚物。
- 一種藥物遞輸載具,其包含:如請求項6之奈米粒子;及一藥物。
- 如請求項7之藥物遞輸載具,其中該藥物係選自抗癌劑、抗增生或化學治療藥物、止痛劑、抗發炎劑、抗寄生蟲劑、抗心律不整劑、抗細菌劑、抗病毒劑、抗凝血劑、抗憂鬱劑、抗糖尿病藥、抗癲癇劑、抗真菌劑、抗痛風劑、抗高血壓劑、抗瘧疾藥、抗偏頭痛藥、抗毒蕈鹼劑、抗腫瘤劑、抗勃起障礙劑、免疫抑制劑、抗原蟲藥、抗甲狀腺劑、抗焦慮劑、鎮靜劑、催眠藥、精神安定劑、β-阻斷劑、強心劑、皮質類固醇、利尿劑、抗帕金森氏病劑、胃腸藥、組織胺受體拮抗劑、去角質劑、脂質調節劑、心絞痛藥物、Cox-2抑制劑、白三烯抑制劑、巨環內酯、肌肉鬆弛劑、營養素、成癮性鎮痛藥、蛋白酶抑制劑、性荷爾蒙、興奮劑、抗滲透劑、抗肥胖藥、認知增強劑、尿失禁藥物、良性前列腺藥物、必需脂肪酸、非必需脂肪酸及此等之組合。
- 一種修飾細胞,其包含:如請求項7之藥物遞輸載具;及一免疫細胞。
- 如請求項9之修飾細胞,其中該免疫細胞係選自T細胞、自然殺手細胞、樹突狀細胞(DCs)、巨噬細胞、微膠質細胞及此等之組合。
- 一種用於抗癌用途的藥學組成物,其包含:如請求項1之嵌段共聚物;及 一抗癌藥物。
- 如請求項11之抗癌藥學組成物,其中該癌症係選自結腸癌、肺癌、骨癌、胰臟癌、皮膚癌、頭癌、皮膚黑色素瘤、眼內黑色素瘤、子宮癌、卵巢癌、直腸癌、胃癌、肛周癌、乳癌、輸卵管癌、子宮頸癌、陰道癌、外陰癌、霍奇金氏病、食道癌、小腸癌、甲狀腺癌、副甲狀腺癌、腎上腺癌、軟組織肉瘤、尿道癌、陰莖癌、前列腺癌、慢性白血病、急性白血病、淋巴細胞淋巴瘤、膀胱癌、腎癌、輸尿管癌及中樞神經系統(CNS)腫瘤。
- 一種用於抗癌用途或用於預防或治療感染之藥學組成物,其包含:如請求項1之嵌段共聚物;一藥物;及一免疫細胞。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20180163379 | 2018-12-17 | ||
KR10-2018-0163379 | 2018-12-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW202039003A TW202039003A (zh) | 2020-11-01 |
TWI726540B true TWI726540B (zh) | 2021-05-01 |
Family
ID=71102199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW108146271A TWI726540B (zh) | 2018-12-17 | 2019-12-17 | 包含第一親水性嵌段、第二疏水性嵌段及能夠特異性結合至硫醇之官能基的嵌段共聚物 |
Country Status (15)
Country | Link |
---|---|
US (1) | US20210346308A1 (zh) |
EP (1) | EP3900704B1 (zh) |
JP (2) | JP7265000B2 (zh) |
KR (1) | KR102354882B1 (zh) |
CN (2) | CN112955127B (zh) |
AU (1) | AU2019407590B2 (zh) |
CA (2) | CA3112314C (zh) |
DK (1) | DK3900704T3 (zh) |
FI (1) | FI3900704T3 (zh) |
PL (1) | PL3900704T3 (zh) |
PT (1) | PT3900704T (zh) |
RS (1) | RS64992B1 (zh) |
SI (1) | SI3900704T1 (zh) |
TW (1) | TWI726540B (zh) |
WO (1) | WO2020130580A1 (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012040513A1 (en) * | 2010-09-22 | 2012-03-29 | The Board Of Regents Of The University Of Texas System | Compositions and methods for the delivery of beta lapachone |
WO2013152059A1 (en) * | 2012-04-05 | 2013-10-10 | The Board Of Regents Of The University Of Texas System | Multicolored ph-activatable fluorescence nanoplatform |
EP3530291A1 (en) * | 2018-02-27 | 2019-08-28 | Universite De Geneve | Bi-functionalizable amphiphilic diblock copolymers, conjugates and uses thereof |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19990014879A (ko) * | 1995-08-10 | 1999-02-25 | 가타오카가즈노리 | 양쪽 말단에 관능기를 갖는 블록 중합체 |
KR100574341B1 (ko) * | 2003-11-18 | 2006-04-26 | 학교법인 성균관대학 | 썰폰아마이드 이용 pH 민감성 블록공중합체의 제조 방법및 그에 의한 블록공중합체와 마이셀 |
KR100732013B1 (ko) * | 2005-03-18 | 2007-06-25 | 성균관대학교산학협력단 | pH 민감성 블록 공중합체 및 이를 이용한 고분자 마이셀 |
KR100665672B1 (ko) * | 2005-04-13 | 2007-01-09 | 성균관대학교산학협력단 | 새로운 온도 및 pH 민감성 블록 공중합체 및 이를 이용한고분자 하이드로겔 |
CA2648099C (en) * | 2006-03-31 | 2012-05-29 | The Brigham And Women's Hospital, Inc | System for targeted delivery of therapeutic agents |
US20090074828A1 (en) * | 2007-04-04 | 2009-03-19 | Massachusetts Institute Of Technology | Poly(amino acid) targeting moieties |
KR20080095130A (ko) * | 2007-04-23 | 2008-10-28 | 한국과학기술연구원 | pH 민감성 블록공중합체를 이용한 약물전달체 제조 및응용 |
KR100838809B1 (ko) | 2007-05-03 | 2008-06-17 | 성균관대학교산학협력단 | 겔강도가 우수한 온도 및 피에치 민감성 블록 공중합체 및이의 제조방법과 이를 이용한 약물전달체 |
KR100941774B1 (ko) * | 2007-09-06 | 2010-02-11 | 성균관대학교산학협력단 | 인체안전성이 우수한 온도 및 피에치 민감성 블록공중합체및 이의 제조방법과 이를 이용한 약물전달체 |
KR101586866B1 (ko) * | 2010-04-14 | 2016-01-21 | 가톨릭대학교 산학협력단 | 약물 전달을 위한 pH-민감성 나노입자 및 이의 제조방법 |
KR101386176B1 (ko) * | 2010-11-12 | 2014-04-18 | 성균관대학교산학협력단 | 피에이치 민감성 폴리머좀 및 이의 제조방법 |
CN103316354A (zh) * | 2013-05-27 | 2013-09-25 | 上海纳米技术及应用国家工程研究中心有限公司 | 肿瘤靶向多肽-聚乙二醇-聚乳酸复合物及制备方法和应用 |
KR101554703B1 (ko) * | 2014-02-21 | 2015-09-23 | 전북대학교산학협력단 | 벤조일옥시신남알데히드-폴리에틸렌글리콜 결합 마이셀에 아연 프로토포르피린을 담지한 pH 감응형 항암 전구약물 및 이의 제조방법 |
EP3325440B1 (en) * | 2015-07-22 | 2020-04-08 | GNT Biotech & Medicals Corporation | Ph-sensitive linkers for delivering a therapeutic agent |
KR102023058B1 (ko) * | 2016-03-25 | 2019-09-19 | 사회복지법인 삼성생명공익재단 | 이중 이온 pH-민감성 공중합체를 이용한 허혈성 뇌질환 치료용 약물 전달체 |
-
2019
- 2019-12-17 JP JP2021517755A patent/JP7265000B2/ja active Active
- 2019-12-17 US US17/278,272 patent/US20210346308A1/en active Pending
- 2019-12-17 PT PT199002528T patent/PT3900704T/pt unknown
- 2019-12-17 TW TW108146271A patent/TWI726540B/zh active
- 2019-12-17 CN CN201980070001.4A patent/CN112955127B/zh active Active
- 2019-12-17 PL PL19900252.8T patent/PL3900704T3/pl unknown
- 2019-12-17 WO PCT/KR2019/017899 patent/WO2020130580A1/ko active Application Filing
- 2019-12-17 RS RS20231134A patent/RS64992B1/sr unknown
- 2019-12-17 KR KR1020190168636A patent/KR102354882B1/ko active IP Right Grant
- 2019-12-17 DK DK19900252.8T patent/DK3900704T3/da active
- 2019-12-17 EP EP19900252.8A patent/EP3900704B1/en active Active
- 2019-12-17 CA CA3112314A patent/CA3112314C/en active Active
- 2019-12-17 CN CN202310921842.XA patent/CN117159491A/zh active Pending
- 2019-12-17 SI SI201930667T patent/SI3900704T1/sl unknown
- 2019-12-17 AU AU2019407590A patent/AU2019407590B2/en active Active
- 2019-12-17 FI FIEP19900252.8T patent/FI3900704T3/fi active
- 2019-12-17 CA CA3206647A patent/CA3206647A1/en active Pending
-
2023
- 2023-04-13 JP JP2023065651A patent/JP2023109749A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012040513A1 (en) * | 2010-09-22 | 2012-03-29 | The Board Of Regents Of The University Of Texas System | Compositions and methods for the delivery of beta lapachone |
WO2013152059A1 (en) * | 2012-04-05 | 2013-10-10 | The Board Of Regents Of The University Of Texas System | Multicolored ph-activatable fluorescence nanoplatform |
EP3530291A1 (en) * | 2018-02-27 | 2019-08-28 | Universite De Geneve | Bi-functionalizable amphiphilic diblock copolymers, conjugates and uses thereof |
Non-Patent Citations (4)
Also Published As
Publication number | Publication date |
---|---|
JP2023109749A (ja) | 2023-08-08 |
WO2020130580A1 (ko) | 2020-06-25 |
EP3900704A4 (en) | 2022-02-09 |
AU2019407590B2 (en) | 2022-08-04 |
JP2022510765A (ja) | 2022-01-28 |
EP3900704B1 (en) | 2023-11-01 |
KR102354882B1 (ko) | 2022-01-25 |
DK3900704T3 (da) | 2023-12-04 |
CA3112314C (en) | 2023-09-19 |
JP7265000B2 (ja) | 2023-04-25 |
PT3900704T (pt) | 2023-11-27 |
CN112955127A (zh) | 2021-06-11 |
SI3900704T1 (sl) | 2024-01-31 |
FI3900704T3 (fi) | 2023-11-30 |
EP3900704A1 (en) | 2021-10-27 |
AU2019407590A1 (en) | 2021-04-08 |
US20210346308A1 (en) | 2021-11-11 |
TW202039003A (zh) | 2020-11-01 |
CN117159491A (zh) | 2023-12-05 |
CA3206647A1 (en) | 2020-06-25 |
PL3900704T3 (pl) | 2024-03-18 |
KR20200074899A (ko) | 2020-06-25 |
CA3112314A1 (en) | 2020-06-25 |
CN112955127B (zh) | 2024-02-27 |
RS64992B1 (sr) | 2024-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Noh et al. | Co-delivery of paclitaxel and gemcitabine via CD44-targeting nanocarriers as a prodrug with synergistic antitumor activity against human biliary cancer | |
Wang et al. | pH-sensitive pullulan-based nanoparticle carrier of methotrexate and combretastatin A4 for the combination therapy against hepatocellular carcinoma | |
Ghaz-Jahanian et al. | Application of chitosan-based nanocarriers in tumor-targeted drug delivery | |
KR100849911B1 (ko) | 종양-표적화 약물-로딩된 입자 | |
US11478493B2 (en) | Fabrication and application of a hetero-targeted nano-cocktail with traceless linkers | |
US11883505B2 (en) | Anticancer drug-containing plant virus particles | |
Nejati et al. | Nanoparticle-based drug delivery systems to overcome gastric cancer drug resistance | |
JP2010511713A (ja) | 薬物送達 | |
CN102666879A (zh) | 模板化的纳米缀合物 | |
WO2011119881A1 (en) | Multi-compartmental macrophage delivery | |
CN102791294A (zh) | 用于多种药物递送的粒子 | |
JP2002502825A (ja) | 経口運搬用共重合体組成物 | |
WO2018049155A1 (en) | Compositions comprising polymeric nanoparticles and mcl-1 antagonists | |
Akhter et al. | Oral delivery of multicompartment nanomedicines for colorectal cancer therapeutics: combining loco‐regional delivery with cell‐target specificity | |
TWI726540B (zh) | 包含第一親水性嵌段、第二疏水性嵌段及能夠特異性結合至硫醇之官能基的嵌段共聚物 | |
KR101809939B1 (ko) | 친수성 및 소수성 약물의 순차적 방출을 위한 나노 약물 전달체 | |
EP2532368A1 (en) | "Composition for oral delivery of biologically-active substances" | |
Augustine et al. | Two-tailed tadpole-shaped synthetic polymer polypeptide bioconjugate nanomicelles for enhanced chemo-photothermal therapy | |
KR102013041B1 (ko) | 항암제가 담지된 나노구조체를 유효성분으로 포함하는 간암 치료용 약학조성물 | |
Jain et al. | The portrayal of macrophages as tools and targets: a paradigm shift in cancer management | |
KR20150054543A (ko) | 간 표적화 나노입자, 이의 제조방법 및 이를 포함하는 약학적 조성물 | |
JP2023533722A (ja) | ナノ粒子およびその製造方法 | |
Alvarez-Lorenzo et al. | Poly (ethylene oxide)-poly (propylene oxide) block copolymer micelles and gels in drug delivery: state-of-the-art and future perspectives | |
Fitzpatrick | MINIMALLY INVASIVE COPOLYMERS FOR POSTERIOR SEGMENT OCULAR THERAPEUTICS | |
Shah et al. | Advancement in polymer therapeutics and characterization |